Tonix Pharmaceuticals Completes Enrollment in BESTFIT Trial of TNX-102 SL for Fibromyalgia

NEW YORK, May 12, 2014-- Tonix Pharmaceuticals Holding Corp. (TNXP), a clinical-stage pharmaceutical company, today announced that it has completed enrollment in the BESTFIT trial of TNX-102 SL for fibromyalgia, after having achieved the randomization goal of 200 subjects.

BESTFIT (BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy) is a 12-week, randomized, double-blind, placebo-controlled trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 2.8 mg taken at bedtime in patients diagnosed with fibromyalgia. The trial commenced in September 2013 and is being conducted at 17 U.S. clinical sites. The primary outcome measure of BESTFIT is the mean change in week 12 average daily pain intensity from baseline on the 11-point Numeric Rating Scale, using a daily telephonic diary. The safety and tolerability of TNX-102 SL are also being assessed in this trial. An ongoing 52-week open-label safety extension study, which will evaluate the long-term safety and tolerability of TNX-102 SL, continues to enroll subjects who have completed BESTFIT.

"The rate of patient recruitment into BESTFIT exceeded expectations," said Seth Lederman, M.D., president and chief executive officer of Tonix. "If successful, BESTFIT will serve as the first of two pivotal trials to support the marketing approval of TNX-102 SL for the management of fibromyalgia. Fibromyalgia is a debilitating syndrome and many patients are not satisfied with the existing treatment options. With enrollment completed in BESTFIT, we look forward to reporting top line data in the fourth quarter of 2014."

About Fibromyalgia

Fibromyalgia is a chronic syndrome characterized by widespread pain, sleep disturbances, fatigue, cognitive dysfunction, depressed mood, and other symptoms. Fibromyalgia can be debilitating and interfere with daily activities. According to the National Institutes of Health, fibromyalgia affects five million adult Americans. It is not known what causes fibromyalgia.

About Tonix Pharmaceuticals Holding Corp.

Tonix is developing innovative prescription medications to treat fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, all characterized by inadequate treatment options, dissatisfaction expressed among patients and physicians, and significant expense burden. Tonix is developing first-in-class prescription products for approval by the Food and Drug Administration (FDA) to address important clinical problems that affect large numbers of patients. Tonix is currently conducting the first anticipated pivotal trial of TNX-102 SL in fibromyalgia, the BESTFIT trial. Tonix expects to begin clinical development of TNX-102 SL in post-traumatic stress disorder in the third quarter of 2014. With TNX-102 SL, Tonix approaches the treatment of people suffering from fibromyalgia and PTSD by targeting their inability to obtain restorative sleep. TNX-201 is in development for episodic tension-type headache, and Tonix expects to begin clinical studies of TNX-201 in the fourth quarter of 2014. To learn more, please visit www.tonixpharma.com.

Laura Colontrelle-Radocaj
Dian Griesel Int'l
New York, NY
P: 212-825-3210
@dgicomm

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.